Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Nimbus Puts Off IPO A While Longer With $400m From Gilead

This article was originally published in Scrip

Executive Summary

Nimbus Therapeutics LLC was considering an initial public offering to fund its early-stage development programs, but with $400m up front from Gilead Sciences Inc. from the sale of its subsidiary Nimbus Apollo Inc., the company can hold off until the market is more favorable for biotechnology IPOs.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064895

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel